---
title: "Key facts: Novartis faces patent expirations; Citigroup issues 'buy' rating; Cosentyx selected for Medicare negotiations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273918674.md"
description: "Novartis is facing revenue challenges due to impending patent expirations on key drugs and is exploring acquisitions of biotech firms to maintain a strong pipeline of protected intellectual property.1Citigroup has initiated a 'buy' rating on Novartis, citing the company as a 'consistent earnings outperformer' and noting the presence of several potential multi-billion-dollar drugs in its pipeline.2Novartis' psoriasis drug Cosentyx is among 15 drugs selected for Medicare price negotiations in 2028, part of the Inflation Reduction Act of 2022's third negotiation round.3"
datetime: "2026-01-28T02:03:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273918674.md)
  - [en](https://longbridge.com/en/news/273918674.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273918674.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273918674.md) | [繁體中文](https://longbridge.com/zh-HK/news/273918674.md)


# Key facts: Novartis faces patent expirations; Citigroup issues 'buy' rating; Cosentyx selected for Medicare negotiations

-   Novartis is facing revenue challenges due to impending patent expirations on key drugs and is exploring acquisitions of biotech firms to maintain a strong pipeline of protected intellectual property.1
-   Citigroup has initiated a 'buy' rating on Novartis, citing the company as a 'consistent earnings outperformer' and noting the presence of several potential multi-billion-dollar drugs in its pipeline.2
-   Novartis' psoriasis drug Cosentyx is among 15 drugs selected for Medicare price negotiations in 2028, part of the Inflation Reduction Act of 2022's third negotiation round.3

### Related Stocks

- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [Novartis AG (NVS.US)](https://longbridge.com/en/quote/NVS.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Novartis Agrees To Acquire Excellergy, Inc.](https://longbridge.com/en/news/280735969.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/en/news/281346305.md)
- [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/en/news/281517197.md)
- [Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus](https://longbridge.com/en/news/281522861.md)
- [Precigen Details Papzimeos Commercial Launch, Hub Growth and J-Code Catalyst at H.C. Wainwright Chat](https://longbridge.com/en/news/281233412.md)